IMAC Holdings (IMAC) announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed CEO, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. Zaslavsky previously served as COO and CEO at Theralink Technologies (THER). Prior to Theralink, Ms. Zaslavsky served as President of Oncology for Myriad Genetics. The board of directors will consist of three independent board members effective today. The board accepted the resignation of BACK co-founders Dr. Matt Wallis and Mr. Ervin from the board. Mr. Ervin will serve as a transition consultant.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BACK: